
Edgar Filing: Babu Yarlagadda S - Form 4

Babu Yarlagad Form 4	da S									
September 05,	2017									
FORM	4 UNITED	STATES	SECU	DITIES /	ND FY	СНАМСІ			PPROVAL	
	SIAILS	ES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549					OMB Number:	3235-0287		
Check this b if no longer subject to Section 16. Form 4 or									January 31, 2005 average urs per . 0.5	
Form 5 obligations may continu <i>See</i> Instructi 1(b).	e. Section 17	rsuant to S (a) of the 30(h)	n							
(Print or Type Res	sponses)									
1. Name and Address of Reporting Person <u>*</u> Babu Yarlagadda S			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer			
			BIOCRYST PHARMACEUTIC. INC [BCRX]				ALS (Check all applicable)			
(Last) (First) (Middle)			3. Date of Earliest Transaction				Director 10% Owner X Officer (give title Other (specify			
4505 EMPER 200	OR BLVD., SI	UITE	(Month/) 08/31/2	Day/Year) 2017			below)	P - Drug Disc		
		4. If Amendment, Date Original Filed(Month/Day/Year)			al	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 				
DURHAM, N	C 27703						Form filed by M Person			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed of	, or Beneficia	ally Owned	
	Transaction Date Ionth/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or of (D)	SecuritiesFBeneficially(1)Owned(1)Following(1)ReportedTransaction(s)(Instr. 3 and 4)	. Ownership Form: Direct D) or Indirect I) Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report	on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
					Perso inforr requi	ons who re nation con red to resp ays a curre	spond to the collec tained in this form ond unless the form ntly valid OMB con	are not n	SEC 1474 (9-02)	
	Tab					sposed of, or convertible	Beneficially Owned securities)			
1. Title of 2. Derivative Con		saction Date /Day/Year)			4. Transact	5. Numbe iorDerivative			7. Title and Amount of Underlying Securities	

Edgar Filing: Babu Yarlagadda S - Form 4



Reporting Owners

Reporting Owner Name / Address	Address Relationships							
	Director	10% Owner	Officer	Other				
Babu Yarlagadda S 4505 EMPEROR BLVD. SUITE 200 DURHAM, NC 27703			Senior VP - Drug Discovery					
Signatures								
/s/ Alane P. Barnes, by power of attorney	s/ Alane P. Barnes, by power of attorney		09/05/2017					
**Signature of Reporting Person		Da	te					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors

(1) determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.